UBA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Of note two of our confirmed somatic variants (R182H, E597A) co-emerged with a NRAS variant after treatment (R-FC for CLL + t-MDS R182H; imatinib for ET + CML + sMF E597A), which again suggests the contribution of UBA1 variants to clonal fitness.